DERMATOLOGISTS' CASE FILES
Management of Malignant and Premalignant Skin Lesions

This educational supplement to Skin & Allergy News was supported by an educational grant from 3M Pharmaceuticals. This supplement was jointly sponsored by The Elsevier Office of Continuing Medical Education (EOCME), an ACCME accredited provider, and Skin & Allergy News and is based on faculty interviews.

•Topic Highlights
•Faculty
•Target Audience
•Educational Needs
•Learning Objectives
•CME Recognition

To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 5.

Topic Highlights

• Introduction
• Management of Patient With a Crusted Papule on the Nose
• A Middle-Aged Man With Psoriasis and Plantar Warts

Faculty

Stephen K. Tyring, MBA, MD, PhD
Professor of Dermatology
University of Texas
Health Science Center
Houston
Dr. Tyring has received grant funding, honoraria, or served on advisory boards for, and/or is a consultant to 3M Pharmaceuticals, Abbott Laboratories, Amgen, Inc., GlaxoSmithKline, Merck & Co., Inc., and Novartis Pharmaceuticals.

Robert T. Brodell, MD
Professor of Internal Medicine
Dermatology Section
Northeastern Ohio Universities College of Medicine
Rootstown
Dr. Brodell is a speaker for 3M Pharmaceuticals.

Target Audience

This educational activity has been developed for dermatologists and other health care providers involved in the diagnosis and management of skin disorders for which immune response modifier (IRM) therapy might be considered.

Educational Needs

Skin disorders related to photodamage pose a major health issue that has implications involving morbidity, mortality, and health resource utilization. Various types of destructive therapies offer the potential for high cure rates for lesions such as actinic keratoses. However, the therapies are not 100% effective, do not eliminate the risk of recurrence, and can cause scarring that patients often find unacceptable. Because photodamage to the skin arises over a long period of time, many patients may not be good candidates for destructive therapies.

Topical and systemic therapies appeal to many patients seeking less invasive alternatives to conventional approaches to treatment. However, some of these therapies have yielded mixed results. Recently, IRM therapy has evolved as another option for management of actinic keratosis, superficial basal cell skin cancer, and possibly other lesions associated with photodamage.

In this supplement to Skin & Allergy News, dermatology specialists share clinical case experiences that illustrate the application of IRM therapy in varied skin diseases.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

• identify and describe therapeutic options for skin diseases caused by photodamage.

• describe the results of a clinical application of IRM therapy for a patient with actinic keratosis.

• discuss one clinician's experience with an IRM as therapy for recalcitrant plantar warts.

CME Recognition

This Skin & Allergy News supplement is recognized by the American Academy of Dermatology (AAD) for 1 hour of AAD Category 1 Continuing Medical Education (CME) Credit and may be used toward the AAD's CME Award.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Skin & Allergy News. The EOCME is accredited by the ACCME to provide continuing medical education for physicians.

The EOCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: December 2006 to November 30, 2007.

Copyright © 2006 Elsevier Inc.

---